Wed, Feb 06, 2013 at 09:05
Brokerage: Credit Suisse
Target: Rs 840
Rationale: The doxil opportunity is still under-appreciated by the market, as it's likely to remain a low competition product and now becomes part of the base business.
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.